Sage Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Highlights Pipeline and Business Progress

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/9/2026

1. TTAN
2. BRZE
3. CHYM
4. USO
5. QCOM
6. IRT
7. ASO
8. PHVS
9. QQQ
10. UNFI

Go back to Sage Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Highlights Pipeline and Business Progress

Sage Therapeutics (SAGE) PT Lowered to $58 at Stifel

February 24, 2022 10:19 AM EST

Stifel analyst Paul Matteis lowered the price target on Sage Therapeutics (NASDAQ: SAGE) to $58.00 (from $75.00) while maintaining a Buy rating.

The analyst commented, "We are maintaining our Buy rating on Sage following their 4Q21 update. Even with mixed CORAL data, we still... More

SAGE Therapeutics (SAGE) Tops Q4 EPS by 4c

February 24, 2022 6:39 AM EST

SAGE Therapeutics (NASDAQ: SAGE) reported Q4 EPS of ($2.12), $0.04 better than the analyst estimate of ($2.16). Revenue for the quarter came in at $1.64 million versus the consensus estimate of $1.97 million.

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.

... More